Physician profile
Dirck Curry
NPI 1952339293
$262.97
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $59.00 · 2021: $13.76 · 2022: $13.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.87 | 2019 | |
| Amgen INC. | $47.08 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $34.57 | 2019 | |
| Lilly USA, LLC | $33.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.65 | 2019-2022 | |
| Alkermes, INC. | $24.79 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dirck Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.